Connor, Clark & Lunn Investment Management Ltd.
Position in NEO — Neogenomics Inc
CIK 1596800
VANCOUVER, A1
Position in NEO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$11,709,889
+$4,749,544 QoQ
Shares Held
802,597
-14.4% QoQ
Ownership
0.625%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#32
of 266 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NEO Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Connor, Clark & Lunn Investment Management Ltd. holds $189,818,037 across 16 Diagnostics & Research names. NEO ranks #5 (6.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MEDP |
Medpace Holdings, Inc.
|
110,353 | $58,441,845 | |
| 2 | GH |
Guardant Health, Inc.
|
215,395 | $32,315,711 | |
| 3 | DHR |
Danaher Corp /De/
|
114,010 | $21,716,624 | |
| 4 | TMO |
Thermo Fisher Scientific Inc.
|
36,269 | $18,183,825 | |
| 5 | NEO |
Neogenomics Inc
This page
|
802,597 | $11,709,889 | |
| 6 | RVTY |
Revvity, Inc.
|
87,145 | $9,695,752 | |
| 7 | MYGN |
Myriad Genetics Inc
|
1,407,860 | $8,038,880 | |
| 8 | CSTL |
Castle Biosciences Inc
|
331,727 | $7,911,688 |
All Filings in NEO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,709,889 | 802,597 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $6,960,345 | 938,052 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $10,324,680 | 877,949 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $4,317,842 | 559,306 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $507,752 | 69,460 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||